onr:"swepub:oai:gup.ub.gu.se/55372"
Search: onr:"swepub:oai:gup.ub.gu.se/55372" > Long-term survival ...
- 1 of 1
- Previous record
- Next record
- To hitlist
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial
- Stadler, R. (author)
- Luger, T. (author)
- Bieber, T. (author)
- show more...
- Kohler, U. (author)
- Linse, R. (author)
- Technau, K. (author)
- Schubert, R. (author)
- Schroth, K. (author)
- Vakilzadeh, F. (author)
- Volkenandt, M. (author)
- Gollnick, H. (author)
- Von Eick, H. (author)
- Strannegard, O. (author)
- show less...
- (creator_code:org_t)
- 2009-07-08
- 2006
- English.
- In: Acta Oncol. - : Informa UK Limited. - 0284-186X. ; 45:4, s. 389-99
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- In a prospective, controlled, randomised, multicentre study 252 patients with totally resected cutaneous melanoma (248 in stage II-III and 4 in stage IV) were either treated with two doses of dacarbazine (DTIC) followed by a 6-month treatment with 3 MU thrice weekly of highly purified natural interferon-alpha (n = 128; arm A) or received no adjuvant treatment (n = 124; arm B). Treatment was well tolerated. After a median follow-up of 8.5 years ITT analysis showed that the difference in survival was statistically significant with respect to melanoma-related deaths (HR = 0.65, CI = 0.46-0.97, p = 0.022) and close to significance with respect to overall survival (HR 0.71, CI 0.49-1.00, p = 0.052). The risk reduction of melanoma-associated death, calculated by Cox proportional hazards modelling, after adjusting for identified predictive variables, was almost 50% (p = 0.002). The overall efficacy of the treatment appeared to be mainly attributable to effects observed in patients with deep and/or metastasizing tumours (HR 0.60, CI 0.40-0.90, p = 0.013).
Keyword
- Adult
- Aged
- Aged
- 80 and over
- Antineoplastic Combined Chemotherapy Protocols/ therapeutic use
- Chemotherapy
- Adjuvant
- Dacarbazine/administration & dosage
- Female
- Humans
- Interferon-alpha/administration & dosage
- Male
- Melanoma/drug therapy/ mortality
- Middle Aged
- Neoplasm Recurrence
- Local/drug therapy/mortality/secondary
- Neoplasm Staging
- Prospective Studies
- Skin Neoplasms/drug therapy/ mortality
- Survival Rate
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Stadler, R.
- Luger, T.
- Bieber, T.
- Kohler, U.
- Linse, R.
- Technau, K.
- show more...
- Schubert, R.
- Schroth, K.
- Vakilzadeh, F.
- Volkenandt, M.
- Gollnick, H.
- Von Eick, H.
- Bergh Thorén, Fr ...
- Strannegard, O.
- show less...
- Articles in the publication
- Acta Oncol
- Acta Oncologica
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
